HEAL: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)
ID: 358819Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is set to release a Notice of Funding Opportunity (NOFO) titled "HEAL: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)" aimed at supporting research that translates addiction-related findings into practical applications to combat the opioid crisis and overdose events. This initiative seeks to identify and address factors influencing substance use and overdose deaths, focusing on developing effective, scalable interventions that integrate evidence-based practices into routine healthcare. Interested small businesses are encouraged to prepare for this opportunity, with applications expected to be solicited after the estimated synopsis post date of August 1, 2025, and closing on October 16, 2025. For further inquiries, potential applicants can contact Dr. Tisha Wiley at tisha.wiley@nih.gov or by phone at 301-594-4381.

    Point(s) of Contact
    Files
    No associated files provided.
    Similar Opportunities
    Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to release a Notice of Funding Opportunity (NOFO) aimed at supporting research for the development of medications to prevent and treat substance use disorders (SUDs) and overdose. This initiative will focus on preclinical and clinical research studies that can rapidly advance candidate interventions toward regulatory approval or clinical adoption, encouraging collaborative efforts among experts in various fields such as pharmacology, toxicology, and clinical trials. While applications are not currently being solicited, interested small businesses are encouraged to begin forming partnerships and developing projects in anticipation of the opportunity, with an estimated synopsis post date of August 15, 2025, and a projected award date of July 1, 2026. For further inquiries, potential applicants can contact Drew Townsend, Ph.D., at drew.townsend@nih.gov or by phone at 301-443-4577.
    HEAL Initiative: Integrative Management of Chronic Pain and Opioid Use Disorder (OUD) for Whole Recovery: Health Systems
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "HEAL Initiative: Integrative Management of Chronic Pain and Opioid Use Disorder (OUD) for Whole Recovery: Health Systems." This initiative aims to develop strategies to enhance the sustainable and effective delivery of integrated care for individuals suffering from both chronic pain and OUD, addressing barriers at the health systems level. The importance of this opportunity lies in its focus on improving collaborative care models and implementation strategies to better manage these co-occurring conditions, which affect a significant portion of the population. Interested applicants, particularly small businesses with expertise in chronic pain management and OUD, are encouraged to prepare for the application process, with the estimated synopsis post date set for January 12, 2026, and the estimated award date anticipated for April 1, 2027. For further inquiries, potential applicants can contact Shelley Su, Ph.D., at IMPOWR@nih.gov or by phone at 301-402-3869.
    HEAL Initiative: Research to Increase Implementation of Substance Use Preventive Services (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity under the HEAL Initiative aimed at enhancing the implementation of preventive services for substance use disorders, specifically focusing on opioid misuse. This initiative invites applications for research that addresses gaps in the dissemination and implementation of prevention services, with a phased R61/R33 award mechanism allowing for up to six years of support, contingent on the successful completion of preliminary milestones. The overarching goal is to establish a sustainable prevention infrastructure that effectively reduces risks associated with substance use, emphasizing equity and community involvement in the research process. Interested applicants can find more information and apply by the deadline of January 16, 2026, with a projected funding amount of $4.65 million for the 2024 fiscal year. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-066.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at accelerating substance use research through the utilization of existing data, specifically under the R21 grant mechanism. This initiative seeks to foster innovative research projects that leverage pre-existing datasets to enhance understanding and treatment of substance use disorders. The total estimated funding for this program is $2 million, with an award ceiling of $200,000 per project and an anticipated three awards to be made. Interested applicants should note that the NOFO is expected to be published in Fall 2024, with applications due in Spring 2025, and the estimated award date is set for April 1, 2026.
    Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)" aimed at supporting research into effective interventions for substance use disorders (SUDs) and overdose. This cooperative agreement encourages applications for preclinical and clinical studies focusing on pharmacotherapies, device-based treatments, digital therapeutics, and behavioral interventions, with the goal of advancing these interventions towards regulatory approval or clinical adoption. The funding amount can reach up to $3 million, and applications are due by 5:00 PM local time, with multiple submission cycles from October 2025 to August 2028. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    HEAL NOFO for the HEAL INTERACT Data Center
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a Notice of Funding Opportunity (NOFO) for the HEAL INTERACT Data Center, aimed at addressing musculoskeletal and peripheral pain through integrated research initiatives. This cooperative agreement seeks to fill knowledge gaps and identify novel research directions in the field, encouraging collaborative investigations among experts in pain mechanisms. While applications are not currently being solicited, potential applicants are urged to prepare meaningful collaborations and responsive projects, with an estimated synopsis post date of September 25, 2025, and a projected award date of August 3, 2026. For further inquiries, interested parties can contact Dr. Rebecca Lenzi at rebecca.lenzi@nih.gov or by phone at 301-408-7447.
    Notice of Intent to Publish a Funding Opportunity Announcement for Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (R43/R44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at supporting the development of medications for Alcohol Use Disorder (AUD) and alcohol-associated organ damage through the Investigational New Drug (IND)-enabling and early-stage development phases. This funding opportunity is specifically targeted at small businesses that can propose innovative therapeutic agents, with a requirement for applicants to present a therapeutic candidate backed by substantial preliminary data demonstrating its viability for clinical application. The initiative is crucial for advancing potential treatments closer to U.S. Food and Drug Administration (FDA) approval, with the NOFO expected to be published on January 16, 2025, and applications due by April 5, 2025. The estimated award date is September 30, 2025, and projects may begin as early as December 1, 2025, with encouragement for women-owned and socially or economically disadvantaged businesses to apply.
    Notice of Intent to Publish a Funding Opportunity Announcement for Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (R41/R42 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at supporting the development of medications for Alcohol Use Disorder (AUD) and Alcohol-Associated Organ Damage (AAOD) through the Investigational New Drug (IND)-enabling and early-stage development process. Eligible applicants, specifically small businesses, are invited to propose projects that advance therapeutic candidates with a solid foundation of background data, facilitating their transition to preclinical and clinical phases of development. This initiative is crucial for addressing the public health challenges associated with alcohol-related conditions, with the NOFO expected to be published on January 16, 2025, and applications due by April 5, 2025. The funding will utilize R41/R42 activity codes, and the estimated award date is September 30, 2025, with project start dates anticipated for December 1, 2025.
    Forecast for HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative for the development of non-addictive analgesic therapeutics, specifically targeting small molecules and biologics to treat pain. This cooperative agreement aims to accelerate the discovery and optimization of promising therapeutic candidates, facilitating their readiness for Phase II clinical studies, while excluding basic research and clinical studies beyond Phase I. The program encourages collaborations among researchers with expertise in pain therapeutics development, with applications expected to be submitted by early 2026, and an estimated award date set for September 2026. For further inquiries, interested parties can contact Dr. Mohamed Hachicha at 301-496-1779 or via email at mohamed.hachicha@nih.gov.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative, titled "Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)." This initiative aims to support early-stage translational research focused on developing and validating tests for non-opioid analgesics, including small molecules and biologics, to address the ongoing opioid crisis and improve pain management. The program anticipates a funding pool of $2.5 million, with plans to award approximately 4-5 grants in FY 2025, and applications are due by January 15, 2027. Interested applicants can find more information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.